Introduction
In patients under mechanical ventilation, the proportion of nosocomial pneumonia cases caused by multiresistant strains of Acinetobacter baumannii is increasing, 1 so an experimental model has been developed. 2 The aims of the study were to evaluate the in vivo efficacy of levofloxacin alone or in combination against A. baumannii and to determine the major pharmacodynamic parameters correlated with the in vivo efficacy of levofloxacin. Two Acinetobacter isolates with different susceptibilities to this drug were used.
Materials and methods

Challenge organisms
Two clinical isolates of A. baumannii with different susceptibilities to levofloxacin, Ab-40 and Ab-60, were studied; they were isolated from the blood of two patients.
In vitro tests
MICs were determined in Mueller-Hinton broth (MHB) (Pasteur Mérieux, Marçy l'Etoile, France). The final inoculum was 10 6 cfu/mL. MBC endpoints were determined by subculture on to Mueller-Hinton agar (Pasteur Mérieux). Escherichia coli ATCC 25922 was used as a control. For levofloxacin, breakpoints recently proposed by the French Committee on Antibiograms 1999 were used: susceptibility, Ͻ4 mg/L; resistance, у4 mg/L.
Mouse model
European guidelines on animal experimentation were followed throughout this study. Transiently neutropenic female C3H/HeN mice (18-20 g) (Iffa-Credo Laboratories, L'Arbresle, France) were anaesthetized and infected by intratracheal instillation of 50 L of a bacterial suspension containing 10 8 cfu/mL, as described previously. 2 Surviving animals were killed on day 5 to avoid unnecessary pain.
Pharmacokinetic parameters in infected mice
A single dose of levofloxacin 100 mg/kg (Hoechst Marion Roussel, Romainville, France) and imipenem 100 mg/kg (Merck Sharp & Dohme, Paris, France) or amikacin 18 mg/kg (Bristol Myers Squibb, Paris, France) was given 3 h after infection. Serum and lung samples were collected 5, 10, 30, 60 and 120 min after injection (three mice per data point). Levofloxacin concentrations were determined by HPLC. The samples were extracted with dichloromethane after adding N-allylpefloxacin as an internal standard. Separation was performed on a Nova-pack C-18 column. 
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and emission at 510 nm). Coefficients of variation for within-and between-day precision were р2% and 8%, respectively, and the lower limit of quantification was 0.1 g/L and 0.1 g/g for plasma and lung, respectively. Imipenem and amikacin concentrations were determined using methods described previously. 2, 3 Pharmacokinetic parameters were evaluated by standard methods; 4 maximum concentration observed (C max ) and elimination half-life were calculated by linear least-squares regression. The inhibitory quotient (IQ) was calculated as C max /MIC. t Ͼ MIC is the time for which the antibiotic concentration exceeded the MIC in serum or lung. The area under the serum concentration-time curve (AUC) was calculated by the trapezoidal rule.
Regimens
In vivo bactericidal effect of therapy. Treatment was initiated 3 h after inoculation. Levofloxacin 100 mg/kg and amikacin 18 mg/kg were administered alone or combined as two ip doses 6 h apart; Imipenem 100 mg/kg was administered alone or combined with levofloxacin as four ip doses at 3 h intervals. The bacterial counts in lungs obtained 3, 6, 9, 12 and 24 h after the first dose were used to determine the maximum bactericidal effect of each regimen; 15 animals were used for each regimen (three animals per data point).
Lungs were weighed and then homogenized in 10 mL of saline. Serial 10-fold dilutions of the homogenates were plated on to trypticase soy agar. The lower limit of detection was 10 2 cfu/g of lung.
Effect of therapy on survival rates. Treatment was initiated 8 h after inoculation. Regimens were the same as those in the in vivo bactericidal experiments except for imipenem, which was administered as five ip doses (20 animals/ regimen).
Screening for emergence of resistant mutants during treatment
Etest strips of levofloxacin were not available, so an Etest strip of ofloxacin was used on Mueller-Hinton agar for screening for mutants resistant to levofloxacin (MIC Ͼ 4 mg/L); this was done when determining the bacterial count in lungs, 24 h after the first dose of levofloxacin.
Results
Pharmacokinetic parameters of levofloxacin, imipenem and amikacin are summarized in Table I . For levofloxacin, a high peak serum concentration was observed with a good Table II shows the efficacy of various regimens against the two strains. Against the strain susceptible to levofloxacin, both levofloxacin and imipenem were weakly bactericidal, slightly reducing the lung bacterial counts compared with values at the start of the treatment. Combination of levofloxacin with imipenem or amikacin did not increase bactericidal activity. All the regimens tested significantly reduced mortality compared with controls (P Ͻ 0.01). Against Ab-40 (the intermediate strain), only imipenem (alone or combined) had a weak bactericidal effect and significantly reduced mortality compared with controls or with animals treated with levofloxacin (P Ͻ 0.01). The bactericidal effect of the levofloxacin-amikacin combination was not superior to that of amikacin alone. No mutants resistant to levofloxacin were isolated after treatment during the various experiments.
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Discussion
Because nearly half of the A. baumannii strains isolated in France are resistant to all available antibiotics except imipenem, new drugs have to be tested. In vitro and animal studies have shown that fluoroquinolones exhibit a concentration-dependent antibacterial activity. 5 In our murine model, the pharmacodynamic properties of levofloxacin were studied using two A. baumannii strains of different susceptibility to this drug. In both serum and lungs, a low AUC/MIC ratio of levofloxacin was associated with lack of bactericidal effect and high mortality, as observed in animals challenged with the non-susceptible strain. The t Ͼ MIC in serum and lungs was longer in mice challenged with the susceptible strain. In a murine pneumococcal pneumonia model, 6 the AUC/MIC ratio for ciprofloxacin or sparfloxacin was the best predictor of survival with a 100% clinical cure when it was у160, irrespective of the method of administration. In a neutropenic rat model of Pseudomonas aeruginosa sepsis, 7 the impact of dose fractionation and altered lomefloxacin MICs on survival was examined. In this model, the significance of AUC/MIC varied with the C max /MIC ratio: a high C max /MIC ratio (10-20) was linked to survival, whereas at lower doses producing C max /MIC ratios of Ͻ10, the AUC/MIC was closely linked to outcome. Several clinical trials of patients treated with ciprofloxacin for Gram-negative pneumonia also identified the AUC/MIC ratio as the most important pharmacodynamic parameter. 8 In our study, AUC/MIC ratios were 347 and 670 in serum and in lungs, respectively, in animals challenged with the susceptible strain but only 5.2 and 10, respectively, in those infected with the intermediate strain. tissue with low pH might explain these results and the absence of synergy between amikacin and either imipenem or levofloxacin. 9 One potential benefit of the combination of levofloxacin with amikacin could be the reduction of selection of mutants resistant to levofloxacin during treatment. However, this point has not been addressed in our study.
